Emmanuel Aziz

• Leading the promotion of Keytruda (pembrolizumab) in key indications: non-small cell lung cancer (NSCLC), urothelial carcinoma, and renal cell carcinoma.

• Driving territory performance through strategic account planning, KOL engagement, and close collaboration with cross-functional teams (medical, access, marketing).
Responsible for Key accounts (universities hospital, national Health insurance and private Hospitals).


• Consistently exceeding sales targets and maintaining high standards of compliance and ethical promotion. overachieved Keytruda sales target in Delta region, reaching 115% of the assigned target.

This performance contributed to enhancing the product’s IMS share, with Delta region achieving MSG of 6.4% in non retail market , despite the national MSG average of 6% by recruiting cases with exceptional approvals in NHI and took the initiative to penetrate governmental hospitals by introducing Keytruda under the Economic Treatment protocol, expanding patient access and driving long-term product growth .

• Coaching and mentoring junior team members, sharing best practices and supporting field execution excellence.

• Promoted Eli Lilly’s oncology portfolio including Verzenio® (abemaciclib) for HR+/HER2- metastatic breast cancer and Cyramza® (ramucirumab) for advanced gastric cancer indications.

• Built and maintained strong relationships with KOLs and HCPs in oncology centers and tertiary hospitals.

• Recognized twice for exceptional Verzenio performance at HI (High Impact) events.
• Successfully led mindset shift among HCPs to adopt Verzenio as a 1st and 2nd line treatment option.
• Awarded “Excellence & Best Achiever – Oncology Business Unit 2021.”
• Achieved 134% of Verzenio sales target in 2023.

Gharbia, Egypt

• Successfully launched Diaflozimet® – EVA Pharma’s first combination of dapagliflozin/metformin – in the Gharbia region, establishing strong market presence.

• Conducted effective scientific detailing and product positioning with diabetologists, internists, and general practitioners.

• Built a solid customer base and strong relationships across private clinics and governmental hospitals.

Achievements:
• Best Achiever Award (2021): Achieved 132% of annual target ranked #1 in diabetes domain across the company